These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9864283)

  • 41. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E; Ferry S; Mach U; Stark H; Leriche L; Boraud T; Gross C; Sokoloff P
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
    Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M
    Synapse; 2008 May; 62(5):345-51. PubMed ID: 18297692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
    J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Colpaert F; Marien M
    Recept Channels; 2003; 9(5):335-8. PubMed ID: 14527878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Bélanger N; Grégoire L; Bédard P; Di Paolo T
    Endocrine; 2003 Jun; 21(1):97-101. PubMed ID: 12777709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion.
    Schneider JS; McLaughlin WW; Roeltgen DP
    Neurology; 1992 Aug; 42(8):1565-72. PubMed ID: 1641154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.
    Luan L; Ding F; Ai Y; Andersen A; Hardy P; Forman E; Gerhardt GA; Gash DM; Grondin R; Zhang Z
    Cell Transplant; 2008; 17(4):417-25. PubMed ID: 18522244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
    Xue YL; Wang ZF; Zhong DG; Cui X; Li XJ; Ma XJ; Wang LN; Zhu K; Sun AM
    Artif Cells Blood Substit Immobil Biotechnol; 2000 Jul; 28(4):337-45. PubMed ID: 10928703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys.
    Schneider JS; Roeltgen DP
    Brain Res; 1993 Jul; 615(2):351-4. PubMed ID: 8364742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.
    Schneider JS; Kovelowski CJ
    Brain Res; 1990 Jun; 519(1-2):122-8. PubMed ID: 2397401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mannich's compounds on the basis of benzothiazole as a potential anorectic].
    Holbová E; Wildt S
    Cesk Farm; 1984 Jul; 33(6):230-4. PubMed ID: 6498956
    [No Abstract]   [Full Text] [Related]  

  • 54. Acute pediatric exposure to pramipexole dihydrochloride (Mirapex).
    Hack JB; Powell G; Nelson LS; Hoffman RS; Howland MA
    J Toxicol Clin Toxicol; 1999; 37(7):891-2. PubMed ID: 10630277
    [No Abstract]   [Full Text] [Related]  

  • 55. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    Eur J Pharmacol; 1997 May; 325(2-3):137-44. PubMed ID: 9163560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of talipexole on contraversive rotation and functional impairment in MPTP-induced chronic hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    Jpn J Pharmacol; 1998 Jul; 77(3):227-33. PubMed ID: 9717770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
    Kurlan R; Kim MH; Gash DM
    Mov Disord; 1991; 6(2):111-8. PubMed ID: 2057003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    J Pharmacol Exp Ther; 1998 Dec; 287(3):983-7. PubMed ID: 9864283
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.